371 related articles for article (PubMed ID: 16864753)
1. "Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Markman M
Arch Intern Med; 2006 Jul; 166(14):1446-8. PubMed ID: 16864753
[No Abstract] [Full Text] [Related]
2. [Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations].
Hanauske AR
Med Klin (Munich); 1996 Apr; 91 Suppl 3():68-70. PubMed ID: 8692122
[No Abstract] [Full Text] [Related]
3. New adaptive method for phase I trials in oncology.
Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
[TBL] [Abstract][Full Text] [Related]
4. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
5. Risks and benefits associated with novel phase 1 oncology trial designs.
Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
[TBL] [Abstract][Full Text] [Related]
6. Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution.
Markman M
Cancer; 2007 Oct; 110(8):1644-7. PubMed ID: 17879372
[No Abstract] [Full Text] [Related]
7. Phase 1 clinical trials in oncology.
Miller MJ
N Engl J Med; 2005 Jun; 352(23):2451-3; author reply 2451-3. PubMed ID: 15948270
[No Abstract] [Full Text] [Related]
8. Risks and benefits of phase 1 oncology trials, revisited.
Kurzrock R; Benjamin RS
N Engl J Med; 2005 Mar; 352(9):930-2. PubMed ID: 15745986
[No Abstract] [Full Text] [Related]
9. Integrin inhibitors reaching the clinic.
Stupp R; Ruegg C
J Clin Oncol; 2007 May; 25(13):1637-8. PubMed ID: 17470853
[No Abstract] [Full Text] [Related]
10. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
11. Dose selection in phase I studies: why we should always go for the most effective.
Haines IE
J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
[No Abstract] [Full Text] [Related]
12. Dose selection in phase I studies: why we should always go for the top.
Sleijfer S; Wiemer E
J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
[No Abstract] [Full Text] [Related]
13. Some notable properties of the standard oncology Phase I design.
Hather GJ; Mackey H
J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
[TBL] [Abstract][Full Text] [Related]
14. [Contribution of Japan to develop new anticancer agents].
Sajjo N
Gan To Kagaku Ryoho; 1996 Jan; 23(2):242-6. PubMed ID: 8611054
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring in oncology: does it have a future?
McMahon G; O'Connor R
Bioanalysis; 2009 Jun; 1(3):507-11. PubMed ID: 21083145
[No Abstract] [Full Text] [Related]
16. Discrete event simulation applied to pediatric phase I oncology designs.
Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
[No Abstract] [Full Text] [Related]
17. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic intent in the conduct of phase I antineoplastic drug trials.
Markman M
Oncology; 2009; 76(3):149-50. PubMed ID: 19169045
[No Abstract] [Full Text] [Related]
19. Ovarian cancer and the battle of the specialists.
McGuire WP
J Clin Oncol; 2007 Aug; 25(23):3554-5; author reply 3557-8. PubMed ID: 17687166
[No Abstract] [Full Text] [Related]
20. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.
Fleming GF
J Clin Oncol; 2007 Jul; 25(20):2983-90. PubMed ID: 17617530
[No Abstract] [Full Text] [Related]
[Next] [New Search]
